Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

What was studied

This study compared epcoritamab plus R2 with usual care. R2 is lenalidomide plus rituximab. The cancer was relapsed or refractory follicular lymphoma. This cancer often comes back. Each remission tends to be shorter. The abstract says new treatments are needed. The epcoritamab group came from arm 2 of the EPCORE NHL-2 trial, with 111 people. The comparison group came from health records, with 380 people. It was an adjusted comparison, not a head-to-head randomised trial.

What they found

Epcoritamab plus R2 gave better response rates than R2 or chemoimmunotherapy. This held for overall and complete response. Responses lasted longer, with a hazard ratio of 0.29. Complete responses lasted longer, with a hazard ratio of 0.31. Time without progression was longer, with a hazard ratio of 0.43. Overall survival was longer, with a hazard ratio of 0.33.

What it means for patients

The authors say the findings support epcoritamab plus R2 as a chemotherapy-free option. They say it improved response and survival over R2 or chemoimmunotherapy.

Why it is not certain yet

The comparison used health records, not random assignment. The abstract says no direct comparison existed before. The trial group and records group came from different places. Adjusted analyses can only adjust for what was measured.

Source

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

We restate facts from the source record in our own words. The original wording belongs to its publisher.